News

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.
The human metapneumovirus diagnostics market is set to continue its upward trajectory in the upcoming years, projected to reach $0.79 billion by 2029, reflecting a CAGR of 10.1%.
There's currently no specific treatment or vaccine for hMPV. Most cases are mild and can be managed at home with rest and symptom relief such as taking medication (paracetamol or ibuprofen) for ...
Abstract and The Classification of Human Metapneumovirus Abstract Until relatively recently there had been episodes when children had been admitted into hospitals with symptoms that were similar ...
Vermont has the second lowest state fatality rate in the US (148.2 per 100K; Hawaii 113.6/100K). Mississippi (465.8/100K) and ...
Vermont has the second lowest state fatality rate in the US (147.9 per 100K; Hawaii 113.5/100K). Mississippi (465.6/100K) and ...
Human metapneumovirus (hMPV), a respiratory pathogen identified in 2001, is a substantial cause of community-acquired respiratory infections across all age groups. This Review explores the impact of ...
Health authorities and clinicians across China are warning of a significant surge in COVID‑19 infections this July, driven by the NB.1.8.1 variant—a descendant of the JN.1 lineage that now dominates ...
A new article published in Nature offers a promising path toward a shorter, more effective treatment for tuberculosis (TB), a ...
With an increasing geographic footprint, it is important for clinicians to be able to find a treatment for coccidioidomycosis ...